Regulatory T cells (Tregs) have been shown to play a crucial role in maintaining self-tolerance and suppressing autoimmunity. The forkhead transcription factor, FoxP3, is a key molecule necessary and sufficient for Tregs development and function. We found that the promoter DNA-binding activity of AP-1 transcription factors, which are required for T-cell activation and which activation are silenced in T-cell anergy, is selectively inhibited in the neutrally occurring CD4+CD25+ Tregs upon TCR and CD28 stimulation. The impaired AP-1 DNA binding is not due to the decreased nuclear translocation of AP-1 family transcription factors including c-Jun, JunB and c-Fos. In vitro expression of FoxP3 dramatically suppresses both the transcriptional activity and promoter DNA-binding of AP-1. This inhibitory activity of FoxP3 requires its interaction with c-Jun, and FoxP3/c-Jun interaction requires TCR/CD28 stimulation in Tregs. Interestingly, FoxP3 interacts with c-Jun possibly depend on c-Jun phosphorylation, because treatment of cells with the inhibitor of JNK (c-Jun N-terminal Kinase) or deletion of the JNK-docking sites from c-Jun inhibited FoxP3/c-Jun interaction. Moreover, expression of FoxP3 alters c-Jun subnuclear localization, indicating that FoxP3 inhibits AP-1 transcription activity and sequestering c-Jun from the """"""""active sites"""""""" to some """"""""silent sites"""""""" in the nucleus. We therefore hypothesize that one mechanism that FoxP3 maintains Treg functions is by suppressing AP-1 transcriptional activation. Given that AP-1 family transcription factors compose Jun (c-Jun, JunB &JunD) and Fos (c-Fos, Fra1 and FosB etc.) proteins, it is possible that FoxP3 may also interacts these proteins to inhibit AP-1 DNA binding. Therefore, we will test our hypothesis by determining 1) the interactions of FoxP3 with AP-1 family transcription factors and 2) the functional consequences of FoxP3/AP-1 crosstalk in Tregs.

Public Health Relevance

PROJECT NARRATIVE Results from the proposed research will likely uncover a novel molecular mechanism underlying how FoxP3 maintain the functions of Tregs, an immune cell population that suppresses autoimmune diseases, such as rheumatoid arthritis and diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Research Grants (R03)
Project #
5R03AI073596-02
Application #
7835571
Study Section
Cellular and Molecular Immunology - A Study Section (CMIA)
Program Officer
Lapham, Cheryl K
Project Start
2009-05-08
Project End
2011-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
2
Fiscal Year
2010
Total Cost
$72,275
Indirect Cost
Name
University of Missouri-Columbia
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
153890272
City
Columbia
State
MO
Country
United States
Zip Code
65211